VTGN News and Press, VistaGen Therapeutics Inc. From 06/23/22

VistaGen Therapeutics press release (NASDAQ:VTGN): FY GAAP EPS of -$0.25 misses by $0.03. Revenue of $1.11M (+1.8% Y/Y) misses by $0.21M. At March 31, 2022, the Company had cash and cash equivalents of approximately $68.1 million. Completed last patient out milestone for PALISADE-1 Phase 3 cl...

Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA consensus that data from nonc...

BB, CAMP, FDX, SWBI, VTGN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that the last patient h...

PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder FDA Fast Track designation granted Topline results anticipated mid-2022 VistaGen Therapeutics, Inc. (Nasdaq: VTGN)...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has scheduled a conference call a...

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a confe...

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that the clinica...

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clin...

3 Penny Stocks to Add to Your Watchlist This Month With another day of trading penny stocks over, there is a lot to be excited about. Over the past week, we have seen some major stock market movements. While this can lead to large losses, it can also lead to very sizable gains. To under...